Genmab A/S (NASDAQ:GMAB – Get Free Report) and Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability and institutional ownership.
Valuation and Earnings
This table compares Genmab A/S and Cardio Diagnostics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genmab A/S | $3.72 billion | 7.35 | $963.00 million | $1.27 | 34.48 |
| Cardio Diagnostics | $10,000.00 | 500.24 | -$6.50 million | ($2.92) | -0.58 |
Genmab A/S has higher revenue and earnings than Cardio Diagnostics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations for Genmab A/S and Cardio Diagnostics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genmab A/S | 0 | 3 | 9 | 1 | 2.85 |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
Genmab A/S currently has a consensus price target of $43.39, suggesting a potential downside of 0.92%. Given Genmab A/S’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Genmab A/S is more favorable than Cardio Diagnostics.
Insider & Institutional Ownership
7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 9.0% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Genmab A/S and Cardio Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Genmab A/S | 19.08% | 14.89% | 7.73% |
| Cardio Diagnostics | -43,133.33% | -82.28% | -76.03% |
Risk & Volatility
Genmab A/S has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500.
Summary
Genmab A/S beats Cardio Diagnostics on 11 of the 15 factors compared between the two stocks.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
